Background {#Sec1}
==========

Patients with nosocomial pneumonia caused by methicillin-resistant *Staphylococcus aureus* (MRSA) have been increasing over the past half century. Approximately 20--40 % of all hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) \[[@CR1], [@CR2]\] and the number of MRSA pneumonia patients is increasing in step with aging of the population \[[@CR3]\]. Several guidelines \[[@CR4], [@CR5]\], including Japanese guidelines for nursing and healthcare-associated pneumonia (NHCAP) \[[@CR6]\] and HAP \[[@CR7], [@CR8]\], suggest the use of anti-MRSA antimicrobials in pneumonia patients when the risks of MRSA are suggested. However, there have been only a few clinical studies that describe the pathogenicity of MRSA in bacterial pneumonia and accurate diagnostic methods for evaluating MRSA pneumonia \[[@CR9]--[@CR11]\]. Generally, the diagnostic criteria of respiratory infection caused by MRSA are positive results of a quantitative culture of MRSA over 10^6^ colony forming units (CFU)/ml in sputum samples, 10^4^ CFU/ml in lower respiratory specimens and/or phagocytosis of *S. aureus* by polymorphonuclear neutrophils \[[@CR4]\]. However, it is occasionally difficult to differentiate whether the detected MRSA is a true causative pathogen of pneumonia or only reflective of colonization when MRSA is cultured from the lower respiratory tract samples. Physicians should carefully consider whether or not cultured MRSA is actually causative in each case because many patients fulfill these criteria and improve without anti-MRSA agents in real-world clinical settings. Differentiation of MRSA as a cause of pneumonia or merely colonization remains an important clinical issue and is of a particular interest in clinical settings.

We hypothesized that the percentage of *S. aureus* clones in bronchoalveolar lavage fluid (BALF) directly obtained from the affected lesions of pneumonia identified by chest CT might be helpful to distinguish true MRSA pneumonia from colonization of MRSA. In the present study, we used the data from the pneumonia registry, which included 16S ribosomal RNA gene analyses of BALF, and patients with pneumonia in whom MRSA was cultured from the respiratory samples were enrolled. Then we divided these patients into two groups: Group A included MRSA pneumonia patients treated with anti-MRSA agents and Group B were patients with MRSA cultured from respiratory samples but who improved without anti-MRSA treatment, and the clinical features of these two groups were compared.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Among 248 Japanese patients with community-acquired pneumonia (CAP), healthcare-associated pneumonia (HCAP) and HAP at the University of Occupational and Environmental Health, Japan and referred hospitals between April 2010 and January 2015, 42 patients with positive cultures for MRSA from respiratory specimens (i.e., sputum, endobronchial aspirates and BALF) were enrolled (Fig. [1](#Fig1){ref-type="fig"}). This cohort included patients in previous studies of CAP \[[@CR12]\] and HCAP \[[@CR13]\]. Patients who had MRSA positively cultured from respiratory specimens were divided into two groups: Group A consisted of patients that had been treated with anti-MRSA agents, and Group B included patients that had been treated without anti-MRSA agents, and the clinical features of these two groups were compared. This study was approved by the Human and Animal Ethics Review Committee of the University of Occupational and Environmental Health, Japan (No.09-118), and all patients provided their written informed consent.Fig. 1A flow chart of the study participants. CAP: community-acquired pneumonia, HCAP: healthcare-associated pneumonia, HAP: hospital-acquired pneumonia, MRSA: methicillin-resistant *Staphylococcus aureus*, BALF: bronchoalveolar lavage fluid

Definitions {#Sec4}
-----------

The diagnosis of pneumonia was made by the fulfillment of the following three criteria: (1) at least one of the following clinical symptoms (a fever ≥ 37 °C, cough, purulent sputum, moist rales, pleural pain, dyspnea, or tachypnea); (2) new infiltrates on a chest X-ray or computed tomography (CT); and (3) at least one sign of systemic inflammation (a white blood cell (WBC) count \> 10,000/mm^3^ or \< 4,500/mm^3^ or an increased C-reactive protein (CRP) level). The definitions of CAP, HCAP and HAP were made according to the Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) guidelines. Briefly, CAP was defined as pneumonia acquired in the community with no risk factors for HCAP. HCAP was defined as pneumonia acquired in the community with one or more of the following risk factors: (a) hospitalization for 2 days in the preceding 90 days; (b) residence in a nursing home or extended care facility; (c) home infusion therapy (including antibiotics); (d) long-term dialysis (including hemodialysis and peritoneal dialysis) within 30 days of entering the study; and (e) home wound care. HAP was defined as pneumonia acquired in the hospital ≥ 48 h after admission \[[@CR4], [@CR14]\]. The criteria for aspiration risk factors, such as neurologic dysphagia, anatomical abnormalities of the upper aerodigestive tract and poor oral hygiene defined by Marik et al. \[[@CR15]\] were used, and patients with gastroesophageal disorders (including disruption of the gastroesophageal junction) were included in this study.

Data and sample collection {#Sec5}
--------------------------

The laboratory findings and radiological information on chest X-rays and/or CT were collected. BALF specimens using 40 ml of sterile saline were obtained from lung lesions of pneumonia, as previously described \[[@CR12], [@CR13]\].

Evaluation of the clinical efficacy {#Sec6}
-----------------------------------

The clinical efficacies of the antimicrobials were evaluated by an improvement in the clinical symptoms, laboratory and chest radiography findings, which fulfill the definitions proposed by the Japan Society of Chemotherapy \[[@CR16]\]. The treatment medication for pneumonia was considered to be clinically "effective" when more than three of the following criteria were satisfied: (1) improvement or complete resolution of the clinical symptoms, (2) improvement in the body temperature to ≤ 37 °C, (3) chest radiography score of ≤ 70 % of the previous value, (4) WBC count ≤ 9,000/mm^3^ and (5) CRP level ≤ 30 % of the previous value. When the efficacy criteria were not satisfied for any reason, the case was considered to be "ineffective." Physicians followed the guidelines for CAP, HCAP and HAP to use anti-MRSA agents as the first antimicrobial treatment. As the present study was a retrospective cohort study, there were no strict criteria that regulate an intervention of anti-MRSA therapy as an additive antibiotic treatment, but clinical response to antibiotics was firstly evaluated three days after the start of antimicrobial treatment, physicians decided to add anti-MRSA agents when the clinical response to antimicrobials were ineffective with positive culture results for MRSA.

Criteria for the identification of bacterial isolates {#Sec7}
-----------------------------------------------------

### Microbiological evaluation using cultivation methods {#Sec8}

Cultivation of BALF and sputum samples was performed as previously described \[[@CR12], [@CR13]\]. The samples were inoculated onto the appropriate Vitek apparatus with or without the associated API identification strip using the Vitek 2 apparatus (bioMerieux), and bacterial identification was confirmed according to an identification percentage of more than or equal to 90 %. When the percentage was less than 90 %, subsequent bacterial identification was performed using API. Each macroscopically recognized bacterial colony containing normal bacterial flora was recorded as normal flora. All *S. aureus* isolates were identified according to a morphologic analysis of the bacterial colony, Gram staining and catalase and coagulase tests. MRSA was identified if the minimum inhibitory concentration of oxacillin was ≥ 4 μg/ml.

### Total cell count, cell lysis efficiency analysis and bacterial identification using the molecular method {#Sec9}

Using BALF specimens, the total bacterial cell count and cell lysis efficiency were evaluated using epifluorescent microscopy, and DNA extraction, amplification of the 16S rRNA gene using polymerase chain reaction (PCR), clone library construction and a sequencing analysis were performed, as previously described \[[@CR12], [@CR13], [@CR17]--[@CR20]\]. Detected DNA sequences were then compared with those of the type strains using the basic local alignment search tool (BLAST) algorithm, as described previously. The 16S rRNA gene sequences of type strains were obtained from the DNA Data Bank of Japan (<http://www.ddbj.nig.ac.jp/>) and the Ribosomal Database Project II (<http://rdp.cme.msu.edu/>) \[[@CR12], [@CR13], [@CR17]--[@CR20]\].

Evaluation of the radiologic findings {#Sec10}
-------------------------------------

Chest X-rays or CT performed within 48 h of the onset of pneumonia were analyzed and evaluated by two experienced respirologists without any clinical information. Radiological findings were sorted into four different patterns as follows: "lobar pneumonia pattern" that showed an air-space consolidation limited to one lobe or one segment, "aspiration pneumonia pattern" that showed pulmonary infiltrations in the bilateral lower lobes, "pulmonary abscess pattern" where the infiltrations accompanied the cavity and "others" that included any other remaining patterns of pneumonia, such as bronchopneumonia, according to previous reports \[[@CR21], [@CR22]\].

Statistical analysis {#Sec11}
--------------------

The baseline characteristics were summarized using descriptive statistics. Continuous variables were compared using the Mann--Whitney *U*-test and Student's t-tests, while categorical variables were compared using Fisher's exact test or the chi-square test, as appropriate. The SPSS software package (version 19) was used for the statistical analysis, and a *P* \<0.05 was considered statistically significant.

Results {#Sec12}
=======

Clinical characteristics and laboratory findings of the participants {#Sec13}
--------------------------------------------------------------------

The clinical characteristics and laboratory findings of 42 patients from whom MRSA was detected are shown in Table [1](#Tab1){ref-type="table"}. Thirteen (31.0 %) and 29 (69.0 %) patients had been treated with (Group A) and without (Group B) anti-MRSA antimicrobials. Between Groups A and B, the rate of patients with malignancy was significantly higher in Group B (37.9 %, 11/29) than in Group A (7.7 %, 1/13) (*p* = 0.016) (Table [1](#Tab1){ref-type="table"}). In these 42 patients, the risk factors of MRSA, such as the use of corticosteroid or immunosuppressants (14.3 %), nasogastric tube feeding or percutaneous gastrostomy tube feeding (7.1 %), antibiotics use within 90 days (28.6 %), detection of MRSA within 90 days (23.1 %), were observed, however, these findings were not significantly different between the groups (Table [1](#Tab1){ref-type="table"}). In addition, patients with aspiration risks were observed in 54.8 % of the total cohort. Group B included significantly more HCAP patients than Group A (*P* = 0.015), however, the radiological findings were not significantly different between Groups A and B (Table [1](#Tab1){ref-type="table"}).Table 1The clinical characteristics and laboratory findings of 42 patients treated with or without anti-MRSA drugs in this studyClinical variatesGroup AGroup B*P*-valueTreated with anti-MRSA drugsTreated without anti-MRSA drugs(*n* = 13)(*n* = 29)Age ± SD (years)74.8 ± 10.174.6 ± 17.50.764Male: Female10:319:100.458Underlying diseases\*\* None2 (15.4 %)4 (13.8 %)0.898 Malignancies1 (7.7 %)11 (37.9 %)0.016 Cerebrovascular disorders5 (38.5 %)10 (34.5 %)0.813 Chronic pulmonary diseases4 (30.8 %)5 (17.2 %)0.382 COPD2 (15.4 %)2 (6.9 %)0.469 Bronchiectasis/NTM1 (7.7 %)5 (17.2 %)0.370 Interstitial lung diseases1 (7.7 %)1 (3.4 %)0.621 Diabetes mellitus4 (30.8 %)3 (10.3 %)0.178 Dementia4 (30.8 %)6 (20.7 %)0.519 Heart diseases4 (30.8 %)5 (17.2 %)0.382 Hepatic diseases1 (7.7 %)1 (3.4 %)0.621 Renal diseases1 (7.7 %)4 (13.8 %)0.550 Hematology/Collagen-vascular diseases1 (7.7 %)4 (13.8 %)0.550ECOG performance status 3-475.0 % (9/12)60.0 % (15/25)0.371Use of Glucocorticoid\*\*/Immunosuppresant1 (7.7 %)5 (17.2 %)0.37Use of gastric tube1 (7.7 %)2 (6.9 %)0.931Histories/Risks of aspiration8 (61.5 %)15 (51.7 %)0.568Antibiotic therapy in the preceding 90 days5 (38.5 %)7 (24.1 %)0.387History of MRSA detection in the preceding 90 days4 (30.8 %)5 (17.2 %)0.382Type of pneumonia CAP0 (0.0 %)2 (6.9 %)0.161 HCAP2 (15.4 %)15 (51.7 %)0.015 HAP11 (84.6 %)12 (41.3 %)0.099Radiologic findings of Chest CT\* Consolidation7 (63.6 %)12 (41.4 %)0.474 Bronchopneumonia1 (9.1 %)9 (31.0 %))0.052 Complicated with cavitation/abscess formation0 (0.0 %)0 (0.0 %)-- Complicated with atelectasis0 (0.0 %)3 (10.3 %)0.083 Centrilobular nodules (DPB-like)0 (0.0 %)0 (0.0 %)-- Diffuse alveolar shadow (ARDS-like)2 (18.2 %)0 (0.0 %)0.165 Bronchiectasis1 (9.1 %)6 (20.7 %)0.239 Parapneumonic pleural effusion5 (45.5 %)3 (10.3 %)0.082*SD* standard deviation, *COPD* chronic obstractive pulmonary disease, *NTM* nontuberculous mycobacterial infection, *MRSA* methicillin-resistant *Staphylococcus aureus*, *ECOG* Eastern Cooperative Oncology Group, *CAP* community-acquired pneumonia, *HCAP* helathcare-associated pneumonia, *HAP* hospital-acquired pneumonia, *CT* computed tomography, *DPB* diffuse pulmonary bronchiolitis, *ARDS* acute respiratory distress syndrome\*includes diplicates, \*\*corresponds to prednisolone 5 mg daily or greater

Comparison between bacterial cultivation and the clone library method of 16S rRNA gene sequencing analysis {#Sec14}
----------------------------------------------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} shows the comparison of the results of the bacterial culture and bacterial floral analysis using the 16S rRNA gene with the clinical course of the patients. Cultivation results demonstrated that MRSA were isolated in all 19 patients in whom sputum culture was performed, and 37 of 41 (90.5 %) patients excluding No. 33 (BALF culture was not analyzed) showed positive culture results of MRSA using BALF samples. The molecular method detected the *S. aureus* phylotype in 22 patients, whereas 20 patients showed no *S. aureus* phylotypes in the BALF samples (Table [2](#Tab2){ref-type="table"}). In Group A, *S. aureus* was detected in 69.2 % (9 of 13, Cases 1--9) of the patients by both cultivation methods and the molecular method, and the molecular method demonstrated that the *S. aureus* phylotype was predominant in 38.5 % (5 of 13, Cases 1--5) of the BALF specimens (Table [2](#Tab2){ref-type="table"}). In 8 of 13 (61.5 %) Group A patients where *S. aureus* was not the predominant phylotype (Cases 6--13), *S. aureus* comprised a minor population (percentage of clones ≤ 10 %). In these 8 patients (Cases 6--13), no discrepancies were observed between the most occupied bacterial phylotypes by the molecular method and the clinical outcomes after antibiotic therapy. All of the patients with poor clinical outcomes in Group A (5 of 13, Cases 1, 4, 6, 10, 11) had obvious complicated poor prognostic factors, such as asphyxiation due to tracheobronchial secretion, exacerbation of heart failure and aspergillosis.Table 2Comparison of Bacteria Between Conventional Cultivation Methods and 16S rDNA Sequencing Analysis in the Bacterial Infection GroupAgePneumonia typeSputumBALFPrior antibioticsTreatmentsClinical outcomeCultureCultureClone library analysisPredominant phylotype, %*S. aureus*GROUP A 172HAP*not analyzedMRSAStaphylococcus aureus 97.5 %97.5 %*ABKVCMineffective 270VAP*not analyzedMRSAStaphylococcus aureus 91.8 %91.8 %*NoneTEICeffective 378HAP*MRSAMRSAStaphylococcus aureus 91.0 %91.0 %*NoneABKeffective 477HCAP*MRSAMRSAStaphylococcus aureus 53.1 %51.8 %*IPM/CS MINOBIPM, PZFX + CLDM, CZOP + ABKineffective 565HAP*not analyzedMRSAStaphylococcus aureus 50.0 %50.0 %*MEPMMEPM+VCMeffective 676HAP*not analyzedMRSACorynebacterium simulans 41.9 %8.1 %*NoneVCMineffective 761HAP*S. pneumoniae MRSAMRSAHaemophilus influenzae 35.3 %3.5 %*MEPMMEPM + VCMeffective 887HAP*MRSAMRSACorynebacterium spp. 97.8 %2.2 %*SBT/ABPCTEICeffective 966HAP*not analyzedH. influenzae, MRSAHaemophilus influenzae 84.0 %1.1 %*NoneIPM/CS + VCM SBT/ABPCeffective 1082VAP*not analyzedMRSA P. aeruginosaPseudomonas aeruginosa 94.6 %0.0 %*IPM/CSPZFX+VCMineffective 1161HCAP*not analyzedMRSA, Aspergillus fumigatusStreptococcus spp. 90.7 %0.0 %*DRPMDPPM PZFX + CLDM/L-AMB + VCM/TAZ/PIPCineffective 1291HAP*MRSAMRSAStreptococcus oralis 58.5 %0.0 %*MEPMLZDeffective 1387HAP*not analyzedMRSA, NeisseriaNeisseria perflava 95.5 %0.0 %*TEICTEIC, AMKeffectiveGROUP B 1481HAP*not analyzedMRSAStaphylococcus aureus 100 %100.0 %*NoneDRPMeffective 1521VAP*not analyzedMRSAStaphylococcus aureus 88.6 %88.6 %*NoneMEPMeffective 1673CAP*not analyzedMRSAStaphylococcus aureus 60.8 %60.8 %*NoneGRXeffective 1776HCAP*MRSA P. aeruginosaMSSAStaphylococcus aureus 57.1 %57.1 %*NoneTAZ/PIPCineffective 1881HCAP*MRSA P. aeruginosano growthStaphylococcus aureus 55.4 %55.4 %*NoneCZOP + CLDMeffective 1962CAP*MRSAMRSAStaphylococcus aureus 48.7 %48.7 %*FQCPFXeffective 2080HAP*MRSAMRSAStreptococcus intermedius 56.5 %40.6 %*NoneDRPMeffective 2176HAP*MRSAMRSACorynebacterium spp. 25.3 %18.4 %*TAZ/PIPCSBT/ABPCeffective 2222HAP*not analyzedMRSA, A. baumanniiNeisseria elongata 81.2 %15.1 %*TEICIPM/CSeffective 2381HCAP*MRSAMRSAStreptococcus spp. 46.7 %12.0 %*NoneLVFXeffective 2485HAP*not analyzedMRSAStreptococcus oralis/mitis 37.3 %8.0 %*CPFXLVFXeffective 2583HCAP*MRSA, E. coliMRSA, E. coliMoraxella catarrhalis 69.2 %7.7 %*NoneTAZ/PIPCeffective 2676HAP*not analyzedK. pneumoniae, MRSA, Proteus mirabilisCorynebacterium simulans 58.4 %1.3 %*NoneTAZ/PIPCeffective 2785HAP*MRSAMRSAFusobacterium nucleatum 55.7 %0.0 %*NoneLVFXeffective 2861HCAP*not analyzedMRSA, B. cepacia, F. mortiferumRothia spp. 45.2 %0.0 %*NoneMEPMeffective 2945HAP*not analyzedS. maltophilia, MRSAEnterococcus hirae 25.8 %0.0 %*NoneMEPMeffective 3074HCAP*P. aeruginosa MRSAP. aeruginosa, MRSAStreptococcus salivarius 43.0 %0.0 %*NoneMEPMeffective 3180HCAP*not analyzedMRSAStreptococcus spp. 98.9 %0.0 %*UnknownLVFXeffective 3280HCAP*not analyzedMRSAStreptococcus spp. 97.4 %0.0 %*UnknownLVFXeffective 3398HCAP*MRSAnot analyzedStreptococcus spp. 78.8 %0.0 %*UnknownTAZ/PIPCeffective 3480HCAP*MRSAoral bacteriaNeisseria spp. 55.0 %0.0 %*LVFXMEPMeffective 3582HCAP*not analyzedP. aeruginosa, MRSA, StreptococcusStreptococcus oralis/mitis 70.7 %0.0 %*UnknownSBT/ABPCeffective 3664HCAP*not analyzedP. aeruginosa, MRSAPseudomonas aeruginosa 97.4 %0.0 %*NoneTAZ/PIPC + LVFXeffective 3786HCAP*MRSAK. pneumoniae, MRSALactobacillus spp. 51.1 %0.0 %*NoneTAZ/PIPCeffective 3880HCAP*E. coli, MRSAoral bacteriaStreptococcus spp. 45.2 %0.0 %*NoneTAZ/PIPCeffective 3993HCAP*not analyzedMRSA, oral bacteriaCorynebacterium spp. 94.3 %0.0 %*NoneLVFXeffective 4081HAP*not analyzedMRSA, E. coliHaemophilus influenzae 34.5 %0.0 %*NoneTAZ/PIPCeffective 4173HAP*not analyzedEnterobacter cloacae, MRSAEnterobacter asburiae 70.0 %0.0 %*NoneDRPMeffective 4274HAP*MRSACorynebacterium, MRSACorynebacterium simulans 98.9 %0.0 %*TAZ/PIPCTAZ/PIPCeffective*Abbreviations*: *CAP* community-acquired pneumonia, healthcare-associated pneumonia, *HAP* hospital-acquired pneumonia, *VAP* ventilator-associated pneumonia, *MRSA* methicillin-resistant *Staphylococcus aureus*, *BALF* bronchoalveolar lavage fluid, *ABK* arbekacin, *VCM* vancomycin, *TEIC* teicoplanin, *LZD* linezolid, *IPM/CS* imipenem/cilastatin, *MEPM* meropenem, *DRPM* doripenem, *BIPM* biapenem, *CZOP* cefozopran, *SBT/ABPC* sulbactam/ampicillin, *TAZ/PIPC* tazobactam/piperacillin, *CPFX* ciprofloxacin, *LVFX* levofloxacin, *GRNX* garenoxacin, *MINO* minomycin, *CLDM* clindamycin, *L-AMB* liposomal amphotericin B, *NA* not applicable

In Group B, 96.5 % of patients (28 of 29, Cases 14--16, 18--42) showed good clinical outcomes without anti-MRSA antimicrobials; one patient (Case 17) died because of asphyxiation due to tracheobronchial secretion. The *S. aureus* phylotype was a minor population (percentage of clones ≤10 %) or undetectable (0 %) in 10.7 % (3 of 28, Cases 24--26) and 57.1 % (16 of 28, Cases 27--42), respectively, of the patients in Group B who had good clinical outcomes. In addition, 5 of these 28 patients (Cases 14--18) showed that the *S. aureus* phylotype was the most detected phylotype, including one patient (Case 14) with 100 % of the percentage of clones of *S. aureus* phylotype.

Correlation of the percentage of clones of *S. aureus* phylotype and risk factors of MRSA pneumonia {#Sec15}
---------------------------------------------------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows the relationship between the percentage of clones of the *S. aureus* phylotype and the risk factors of MRSA pneumonia among all 42 patients. Gastrostomy or nasogastric tube feeding was significantly negatively correlated with the percentage of clones of *S. aureus* phylotype using the molecular method (Table [3](#Tab3){ref-type="table"}).Table 3Comparison of Bacteria Between Conventional Cultivation Methods and 16S rDNA Sequencing Analysis in the Bacterial Infection GroupRisk factors (Positive/Negative)\*\*The percentage of clones of MRSA phylotype (%)PositiveNegative*P*-valueUse of Glucocorticoid\*\*/Immunosuppressant (6/36)40.2 ± 41.419.0 ± 28.30.305Histories/Risks of aspiration (23/19)18.7 ± 33.225.2 ± 29.20.422Antibiotic therapy in the preceding 90 days (12/30)30.1 ± 40.717.5 ± 25.70.391History of pathogens detection in the preceding 90 days\* (9/30)38.2 ± 35.115.4 ± 28.90.105\*Unknown data in three cases, \*\*"Positive" and "Negative" indicate the number of patients with or without each risk factor, respectively.*Abbreviations*: *MRSA* methicillin-resistant *Staphylococcus aureus*

Discussion {#Sec16}
==========

We analyzed the cultivation results and bacterial phylotypes according to the molecular method using BALF samples in patients with MRSA cultured from respiratory samples, and interestingly, no clones of *S. aureus* were detected in the BALF samples in 47.6 % (20/42) of these patients. Most of the patients (*n* = 28 of 29; 96.5 %) treated without anti-MRSA antimicrobials (Group B) showed favorable clinical outcomes despite the cultivation of MRSA, and these 28 patients were suspected to have non-MRSA pneumonia; the cultured MRSA from the respiratory samples might have been due to colonization in the respiratory tract. In addition, the *S. aureus* phylotype was only a minor population (the percentage of clones ≤ 10 %) in 67.9 % (19/28) of these 28 patients in Group B according to the molecular method, which was compatible with their clinical courses. Several previous reports have described that MRSA is occasionally a non-causative pathogen of pneumonia in some patients \[[@CR23]--[@CR26]\] even when MRSA is cultured from sputum samples, and our results suggest that even when MRSA was cultured using samples obtained from the lower respiratory tract, MRSA was clinically considered not to be a causative agent in more than two-thirds of these patients.

A similar report by Nagaoka et al. showed that approximately half (51.4 %, 36/70) of the patients were considered to have true MRSA pneumonia when hospital-acquired MRSA pneumonia was defined according to the positive responses and/or clinical demand of anti-MRSA agents with a positive culture of MRSA and detection of clustered Gram-positive cocci within polymorphonuclear cells in the respiratory samples, such as BALF or transthoracic aspiration \[[@CR11]\]. Moreover, at least 66.7 % (28/42) of the patients were possibly considered to have MRSA colonization, and MRSA was considered to be a causative pathogen in 33.3 % (14/42) of the patients in this study. These data suggest that it remains clinically controversial whether or not MRSA is a true causative pathogen of pneumonia, even in patients with MRSA cultured from the lower respiratory samples, and the ratio of true MRSA pneumonia in these patients might be lower than previously believed.

Five of 28 (17.9 %) patients in Group B who showed good clinical outcomes without anti-MRSA agents demonstrated that the *S. aureus* phylotype was predominant among the detected bacterial phylotypes in the samples, which may be inconsistent with the colonization of MRSA. The molecular method we used could not evaluate drug resistance, and a differentiation between MRSA and methicillin-susceptible *S. aureus* (MSSA) was not possible in this retrospective study. Spontaneous remission of MRSA pneumonia is another potential explanation. In addition, there are presently no criteria to differentiate causative pathogens using the ratio of bacterial phylotypes in the samples, thus careful discretion is necessary to interpret these data, and further studies are needed to elucidate this issue.

Several guidelines \[[@CR4], [@CR6]--[@CR8]\] and clinical trials \[[@CR11]\] have described the risk factors of MRSA pneumonia. According to a report by Nagaoka et al. \[[@CR11]\] that used a multiple regression analysis for the risk factors of MRSA, a past history of head and neck, esophageal or stomach surgery (odds ratio (OR) 8.63), radiological findings of other than lobar pneumonia (OR 10.2), severity of pneumonia with the Pneumonia Patient Outcomes Research Team (PORT) score 5 (OR 5.23), more than 10^6^ CFU/ml of MRSA using a quantitative culture (OR 12.8), and a single cultivation of MRSA (OR 19.9) were significantly correlated with MRSA pneumonia. More HCAP patients were observed in Group B than in Group A, however, no other factors were significantly different between Groups A and B in this study. When considering the percentage of clones of the *S. aureus* phylotype in BALF samples according to each different risk factor in this study, only the "use of gastric tube feeding" was inversely correlated with the percentage of clones of *S. aureus* (Table [3](#Tab3){ref-type="table"}), suggesting that such condition may be a clue to avoid an abuse of anti-MRSA agents.

The analysis using the 16S rRNA gene can detect only bacterial DNA, and does not equally indicate that the detected bacterial phylotype causes bacterial infection. Therefore, we have been investigating and validating this molecular method in several diseases to compare this molecular method with the results of cultivation methods in several settings \[[@CR12], [@CR13]\]. Further investigations for validating this method should be performed.

Study limitation {#Sec17}
----------------

There are several limitations associated with the present study. First, the universal primers we used for the molecular analysis could not amplify all of the bacterial 16S rRNA genes. The primers we used cover approximately 92 % of the registered bacterial species in the Ribosomal Database Project II database, however, the remaining undetectable bacteria with these primers included no causative pathogens that have been reported in humans \[[@CR19]\]. Second, approximately 100 clones per each clone library were analyzed, meaning that bacterial 16S rRNA gene sequences present at less than 1 % of each sample may not be detectable using this method. Third, this study was retrospective, and anti-MRSA agents were administered with no particular criteria. Fourth, a quantitative culture and evaluation of neutrophil phagocytosis of the organisms were not performed. Fifth, study population was relatively small and elderly patients were mostly included in HCAP or HAP patients, and only two CAP patients were included. Further investigations should be considered to elucidate the data in younger population.

Conclusion {#Sec18}
==========

We evaluated the clinical course and the ratios of bacterial phylotypes in BALF specimens using the clone library method and conventional cultivation methods in patients with MRSA detected by cultivation from respiratory samples. The results of this study demonstrated that these patients were heterogeneous, and approximately two-thirds of these patients might be considered to have MRSA colonization or non-MRSA pneumonia. In addition, the results of the cultivation-independent molecular method we used indicated that the detection of MRSA by cultivation methods may not correctly reflect the pathogenicity of MRSA in patients with pneumonia. Further prospective studies are necessary to elucidate the pathogenicity of MRSA in pneumonia.
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